Kawaida Hiromichi, Kono Hiroshi, Amemiya Hidetake, Saitou Ryou, Yamamoto Atsushi, Hosomura Naohiro, Watanabe Mitsuaki, Kimura Ayako, Furuya Shinji, Shimizu Hiroki, Akaike Hidenori, Kawaguchi Yoshihiko, Sudo Makoto, Itakura Jun, Hayakawa Hiroshi, Shindo Hiroko, Takahashi E I, Takano Shinichi, Fukasawa Mitsuharu, Ichikawa Shintaro, Fujii Hideki, Ichikawa Daisuke
First Department of Surgery, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan
First Department of Surgery, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.
Anticancer Res. 2018 Nov;38(11):6537-6542. doi: 10.21873/anticanres.13019.
BACKGROUND/AIM: Nab-paclitaxel plus gemcitabine (nab-P+Gem) is one of most reliable and effective regimens for borderline or unresectable pancreatic cancer (PC). However, the feasibility and clinical benefits of this regimen have never been evaluated for patients with recurrent PC after pancreatectomy. The aim of this study was to investigate the feasibility of combination therapy with nab-paclitaxel plus gemcitabine (nab-P+Gem) for patients with recurrent PC.
Twenty-two patients with recurrent PC received an intravenous infusion of nab-P (125 mg/m) and Gem (1,000 mg/m) on days 1, 8, and 15 of a 4-week cycle. The primary end-point of this study was completion of the 4 cycles. The secondary end-points were the safety, efficacy, and disease control rate.
The treatment completion rate of the 4 cycles was 90.9%. The objective response rate was 13.6% and the disease control rate was 63.6%. The median progression-free survival was 7.2 months. The most common grade 3 or higher hematological toxicity was neutropenia (72.7%). There was no treatment-related death. Furthermore, the chemotherapeutic effects varied with the time of recurrence.
Combination nab-P+Gem therapy was well-tolerated and effective in patients with recurrent PC.
背景/目的：白蛋白结合型紫杉醇联合吉西他滨（nab-P+Gem）是治疗交界性或不可切除胰腺癌（PC）最可靠且有效的方案之一。然而，该方案对于胰腺癌切除术后复发患者的可行性及临床获益尚未得到评估。本研究旨在探讨白蛋白结合型紫杉醇联合吉西他滨（nab-P+Gem）对复发PC患者进行联合治疗的可行性。
22例复发PC患者在4周周期的第1、8和15天接受nab-P（125mg/m²）和Gem（1000mg/m²）静脉输注。本研究的主要终点为完成4个周期的治疗。次要终点为安全性、疗效及疾病控制率。
4个周期的治疗完成率为90.9%。客观缓解率为13.6%，疾病控制率为63.6%。中位无进展生存期为7.2个月。最常见的3级或更高等级血液学毒性为中性粒细胞减少（72.7%）。无治疗相关死亡。此外，化疗效果随复发时间而异。
nab-P+Gem联合治疗对复发PC患者耐受性良好且有效。
